Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma Mar's Total Liabilities for the quarter that ended in Jun. 2026 was MXN2,871 Mil.
Pharma Mar's quarterly Total Liabilities
declined
from Dec. 2025 (MXN3,020.24 Mil) to Mar. 2026 (MXN2,826.65 Mil) but then
increased
from Mar. 2026 (MXN2,826.65 Mil) to Jun. 2026 (MXN2,871.08 Mil).
Pharma Mar's annual Total Liabilities
increased
from Dec. 2023 (MXN2,722.58 Mil) to Dec. 2024 (MXN3,085.44 Mil) but then
declined
from Dec. 2024 (MXN3,085.44 Mil) to Dec. 2025 (MXN3,020.24 Mil).
The historical data trend for Pharma Mar's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Pharma Mar's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of MXN2,871 Mil mean?
Pharma Mar (MEX:PHM1N) has a Total Liabilities of MXN2,871 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Pharma Mar and its competitors.
Is Pharma Mar's Total Liabilities too high?
Pharma Mar's current Total Liabilities is MXN2,871 Mil. Overall, Pharma Mar has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's Total Liabilities compare to VRTX and REGN?
Pharma Mar's Total Liabilities of MXN2,871 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Pharma Mar and its competitors. Pharma Mar's current Total Liabilities is MXN2,871 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Pharma Mar (MEX:PHM1N) has a current Total Liabilities of MXN2,871 Mil. The stock's GF Value™ is MXN1,734.34, compared to a current price of MXN1,608.38 — trading 7.3% below its estimated fair value. The current Total Liabilities is MXN2,871 Mil. Pharma Mar's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Pharma Mar (MEX:PHM1N), the current Total Liabilities is MXN2,871 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Mar (MEX:PHM1N) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued.
The current stock price of MXN1,608.38 is trading 7.3% below its estimated GF Value™ of MXN1,734.34.
Key valuation signals for MEX:PHM1N:
Total Liabilities: MXN2,871 Mil
GF Value™: MXN1,734.34 vs. price of MXN1,608.38 (7.3% below fair value)
No single metric tells the full story. See the MEX:PHM1N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
68GF Score
Get the complete analysis for MEX:PHM1N
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PHM1N has been successfully added to your 
